Erratum to “Low Baseline Interleukin-17A Levels Are Associated with Better Treatment Response at 12 Weeks to Tocilizumab Therapy in Rheumatoid Arthritis Patients”

Ítems similars

• Low Baseline Interleukin-17A Levels Are Associated with Better Treatment Response at 12 Weeks to Tocilizumab Therapy in Rheumatoid Arthritis Patients
  per: Lee, Sang Jin, et al.
  Publicat: (2015)
• Low Baseline Interleukin-17A Levels Are Associated with Better Treatment Response at 12 Weeks to Tocilizumab Therapy in Rheumatoid Arthritis Patients
  per: Sang Jin Lee, et al.
  Publicat: (2015-01-01)
• Effects of Tocilizumab Therapy on Serum Interleukin-33 and Interleukin-6 Levels in Patients With Rheumatoid Arthritis
  per: CHOI, In Ah, et al.
  Publicat: (2018)
• Efficacy and safety of tocilizumab in Korean patients with active rheumatoid arthritis
  per: Baek, Han Joo, et al.
  Publicat: (2019)
• Tocilizumab Increases Body Weight and Serum Adipokine Levels in Patients with Rheumatoid Arthritis Independently of Their Treatment Response: a Retrospective Cohort Study
  per: Choi, In Ah, et al.
  Publicat: (2020)